Is breast conservation superior to mastectomy in early stage triple negative breast cancer?

被引:17
|
作者
Saifi, Omran [1 ]
Chahrour, Mohamad A. [3 ]
Li, Zhuo [2 ]
Hoballah, Jawad [4 ]
Panoff, Joseph [5 ]
Vallow, Laura A. [1 ]
Zeidan, Youssef H. [6 ]
机构
[1] Mayo Clin, Dept Radiat Oncol, Jacksonville, FL 32224 USA
[2] Mayo Clin, Dept Biostat, Jacksonville, FL 32224 USA
[3] Henry Ford Hosp, Dept Gen Surg, Detroit, MI 48202 USA
[4] Amer Univ Beirut, Fac Med, Beirut, Lebanon
[5] Baptist Hlth, Dept Radiat Oncol, Miami, FL USA
[6] Baptist Hlth South Florida, Lynn Canc Inst, Boca Raton, FL USA
来源
BREAST | 2022年 / 62卷
关键词
Radiotherapy; Triple negative; Breast cancer; Propensity matching; 20-YEAR FOLLOW-UP; CONSERVING SURGERY; RADICAL-MASTECTOMY; RADIATION-THERAPY; SURVIVAL; WOMEN; RADIOTHERAPY; RISK;
D O I
10.1016/j.breast.2022.02.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Compare overall survival (OS) and breast cancer-specific survival (BCSS) outcomes of breast conservative therapy (BCT) and mastectomy in a large cohort of patients with early-stage triple negative breast cancer (TNBC), using a propensity score-based matching approach. Methods: Surveillance, Epidemiology, and End Results (SEER) database was used to study the role of RT in early stage TNBC. Primary end points were OS and BCSS. Cox proportional hazard regression models and Kaplan-Meier plots were used to generate the desired outcomes. Propensity score matching was done to minimize bias. Results: 12,761 patients with T1-2N0M0 TNBC as their first malignancy were retrieved. Of these 7237 had lumpectomy with RT, and 5524 had mastectomy only. Age, race, marital status, tumor laterality, grade and stage, and receipt of chemotherapy were prognostic variables for OS and BCSS. Among 4848 matched subjects, the 5-year OS was significantly higher in patients with lumpectomy and RT (89%) compared to mastectomy alone (84.5%) (p-value <0.001). Similarly, BCSS was significantly higher in patients with lumpectomy and RT (93%) compared to mastectomy alone (91%) (p-value <0.001). On subgroup analysis, patients who are younger than 40 had similar survival outcomes after either mastectomy alone or lumpectomy with RT. However, those who are older than 60, have any grade or T stage had better survival outcomes with lumpectomy and RT. Conclusions: Overall, lumpectomy followed by RT is associated with better OS and BCSS compared to mastectomy in T1-2N0M0 TNBC patients. Further research is needed to determine the optimal treatment strategy for specific patient subgroups.
引用
收藏
页码:144 / 151
页数:8
相关论文
共 50 条
  • [21] Breast Conservation Versus Mastectomy in Triple-Negative Breast Cancer: Two Steps Forward, One Step Back? Reply
    Sabri, Siham
    Abdulkarim, Bassam
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (35) : 4723 - 4724
  • [22] INDICATIONS FOR BREAST CONSERVATION IN EARLY STAGE BREAST-CANCER
    PRESSMAN, PI
    CANCER INVESTIGATION, 1992, 10 (05) : 455 - 460
  • [23] Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better?
    Song, Fei
    Tarantino, Paolo
    Garrido-Castro, Ana
    Lynce, Filipa
    Tolaney, Sara M.
    Schlam, Ilana
    CURRENT ONCOLOGY REPORTS, 2024, 26 (01) : 21 - 33
  • [24] Role of Carboplatin in the Treatment of Triple Negative Early-Stage Breast Cancer
    Valsecchi, Matias E.
    Kimmey, Gerrit
    Bir, Arvinder
    Silbermins, Damian
    REVIEWS ON RECENT CLINICAL TRIALS, 2015, 10 (02) : 101 - 110
  • [25] The landscape of systemic therapy for early stage triple-negative breast cancer
    Lu, Jin-Yu
    Soto, Alvaro Alvarez
    Anampa, Jesus D.
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (11) : 1291 - 1303
  • [26] Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better?
    Fei Song
    Paolo Tarantino
    Ana Garrido-Castro
    Filipa Lynce
    Sara M. Tolaney
    Ilana Schlam
    Current Oncology Reports, 2024, 26 : 21 - 33
  • [27] Advancing immunotherapy for early-stage triple-negative breast cancer
    Di Cosimo, Serena
    LANCET, 2020, 396 (10257): : 1046 - 1048
  • [28] Adjuvant Chemotherapy in early stage Triple-Negative Breast Cancer Patients
    Pfeiler, G.
    Koenigsbergt, R.
    Natter, C.
    Jahn-Kuch, D.
    Hudec, M.
    Zeilinger, R.
    Dittrich, C.
    Singer, C.
    ONKOLOGIE, 2010, 33 : 26 - 26
  • [29] Role of Platinum in Early-Stage Triple-Negative Breast Cancer
    Alyssa La Belle
    Jude Khatib
    William P. Schiemann
    Shaveta Vinayak
    Current Treatment Options in Oncology, 2017, 18
  • [30] Update on the Treatment of Early-Stage Triple-Negative Breast Cancer
    Priyanka Sharma
    Current Treatment Options in Oncology, 2018, 19